Wells Fargo raised the firm’s price target on Keros Therapeutics to $77 from $60 and keeps an Overweight rating on the shares. The firm is increasing its pipeline value and M&A weight in its DCF to better reflect 065’s optionality and increased institutional/strategic interest in metabolic assets, though Wells’ focus remains on 012 as the most meaningful upside driver.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KROS:
- Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Truist biotech analysts hold an analyst/industry conference call
- Keros Therapeutics initiated with an Outperform at William Blair
- Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
- Keros Therapeutics 3.5M share Spot Secondary priced at $40.00
